Surmodics: Pounce use successfully facilitates thrombi-emboli removal below knee

Surmodics announced successful early clinical use of the company’s Pounce LP or Low Profile, Thrombectomy System. The Pounce LP Thrombectomy System, which received U.S. Food and Drug Administration FDA clearance in June 2023, is currently in limited market evaluation LME , with full commercial launch planned following completion of the LME. Surmodics’ Pounce Thrombectomy devices are intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. The new Pounce LP Thrombectomy System is indicated for use in vessels ranging from 2 mm to 4 mm in diameter, sizes typical of vessels found below the knee. The Pounce LP System complements the original Pounce Thrombectomy System, introduced in 2021, which is indicated for use in vessels 3.5 mm to 6 mm in diameter. Dr. Lucas Ferrer Cardona, a vascular surgeon with the Dell Seton Medical Center at the University of Texas Hospital in Austin, was the first physician to use the Pounce LP System. “In our first use of the device, the Pounce LP Thrombectomy System performed exceptionally well in helping our team restore blood flow to the foot for a limb-threatened patient,” he said. “Using the device, we promptly removed acute and subacute thrombus from the mid-peroneal artery below the knee with no adjunctive use of thrombolytics and no embolization. Thrombi or emboli in below-the-knee vessels have traditionally been very challenging to remove. I believe this device holds great promise in filling a major gap in our treatment algorithm.”